Climb Bio Q3 2026 Results: Net Loss of $14.6M, Loss Widens
Climb Bio, Inc. is a clinical-stage biotechnology company focused on immunology and autoimmune diseases, specifically developing product candidates budoprutug and CLYM116. As of October 30, 2026, the company had 58,738,178 shares of common stock outstanding and continues to incur significant losses with no current source of product revenue.
- Key figure
- Net loss $14.6M